These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 9892404)

  • 21. Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay.
    Bostic JR; Brown KE; Young NS; Koenig S
    J Infect Dis; 1999 Mar; 179(3):619-26. PubMed ID: 9952368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunoglobulin M and G immunoblots in the diagnosis of parvovirus B19 infection.
    Chen MY; Lee KL; Hung CC
    J Formos Med Assoc; 2000 Jan; 99(1):24-32. PubMed ID: 10743343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-VP1 and anti-VP2 antibodies detected by immunofluorescence assays in patients with acute human parvovirus B19 infection.
    Pereira RF; Paula WN; Cubel Rde C; Nascimento JP
    Mem Inst Oswaldo Cruz; 2001 May; 96(4):507-13. PubMed ID: 11391423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunoreactivity against linear epitopes of parvovirus B19 structural proteins. Immunodominance of the amino-terminal half of the unique region of VP1.
    Musiani M; Manaresi E; Gallinella G; Venturoli S; Zuffi E; Zerbini M
    J Med Virol; 2000 Mar; 60(3):347-52. PubMed ID: 10630969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parvovirus B19 may have a role in the pathogenesis of juvenile idiopathic arthritis.
    Gonzalez B; Larrañaga C; León O; Díaz P; Miranda M; Barría M; Gaggero A
    J Rheumatol; 2007 Jun; 34(6):1336-40. PubMed ID: 17477467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T-helper cell-mediated interferon-gamma, interleukin-10 and proliferation responses to a candidate recombinant vaccine for human parvovirus B19.
    Franssila R; Hedman K
    Vaccine; 2004 Sep; 22(27-28):3809-15. PubMed ID: 15315862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long term follow up of serostatus after maternofetal parvovirus B19 infection.
    Dembinski J; Eis-Hübinger AM; Maar J; Schild R; Bartmann P
    Arch Dis Child; 2003 Mar; 88(3):219-21. PubMed ID: 12598382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parvovirus B19 infection in Chile: markers of infection and immunity in patients with clinical symptoms.
    Larrañaga C; León O; Díaz P; Miranda M; Norambuena X; Pérez M; Gaggero A
    J Med Virol; 2007 Dec; 79(12):1927-34. PubMed ID: 17935173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Report of a collaborative study to calibrate the Second International Standard for parvovirus B19 antibody.
    Ferguson M; Heath A
    Biologicals; 2004 Dec; 32(4):207-12. PubMed ID: 15572102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of a baculovirus-based VP2 enzyme immunoassay (EIA) to an Escherichia coli-based VP1 EIA for detection of human parvovirus B19 immunoglobulin M and immunoglobulin G in sera of pregnant women.
    Jordan JA
    J Clin Microbiol; 2000 Apr; 38(4):1472-5. PubMed ID: 10747128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans.
    Zuffi E; Manaresi E; Gallinella G; Gentilomi GA; Venturoli S; Zerbini M; Musiani M
    Viral Immunol; 2001; 14(2):151-8. PubMed ID: 11398810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Follow-up study of clinical and immunological findings in patients presenting with acute parvovirus B19 infection.
    Kerr JR; Coyle PV; DeLeys RJ; Patterson CC
    J Med Virol; 1996 Jan; 48(1):68-75. PubMed ID: 8825713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human parvovirus B19 infection in patients with chronic hepatitis B or hepatitis C infection.
    Hsu TC; Chen TY; Lin MC; Tzang BS; Tsay GJ
    J Gastroenterol Hepatol; 2005 May; 20(5):733-8. PubMed ID: 15853987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative evaluation of two commercial enzyme immunoassays for serodiagnosis of human parvovirus B19 infection.
    Enders M; Helbig S; Hunjet A; Pfister H; Reichhuber C; Motz M
    J Virol Methods; 2007 Dec; 146(1-2):409-13. PubMed ID: 17854916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impaired gamma interferon responses against parvovirus B19 by recently infected children.
    Corcoran A; Doyle S; Waldron D; Nicholson A; Mahon BP
    J Virol; 2000 Nov; 74(21):9903-10. PubMed ID: 11024117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Most of the VP1 unique region of B19 parvovirus is on the capsid surface.
    Kawase M; Momoeda M; Young NS; Kajigaya S
    Virology; 1995 Aug; 211(2):359-66. PubMed ID: 7544049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human parvovirus B19: ELISA and immunoblot assays.
    Schwarz TF; Roggendorf M; Deinhardt F
    J Virol Methods; 1988 Jun; 20(2):155-68. PubMed ID: 2843558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface.
    Rosenfeld SJ; Yoshimoto K; Kajigaya S; Anderson S; Young NS; Field A; Warrener P; Bansal G; Collett MS
    J Clin Invest; 1992 Jun; 89(6):2023-9. PubMed ID: 1376332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. False-negative serology in patients with acute parvovirus B19 infection.
    Bredl S; Plentz A; Wenzel JJ; Pfister H; Möst J; Modrow S
    J Clin Virol; 2011 Jun; 51(2):115-20. PubMed ID: 21530386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune response to B19 parvovirus and an antibody defect in persistent viral infection.
    Kurtzman GJ; Cohen BJ; Field AM; Oseas R; Blaese RM; Young NS
    J Clin Invest; 1989 Oct; 84(4):1114-23. PubMed ID: 2551923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.